@article {7449,
	title = {Primary failure of bortezomib in newly diagnosed multiple myeloma-understanding the magnitude, predictors, and significance},
	journal = {Leukemia and Lymphoma},
	volume = {57},
	year = {2016},
	note = {Cited By :2Export Date: 21 February 2017},
	month = {2016},
	pages = {1382 - 1388},
	abstract = {Botezomib-based induction is highly effective for the treatment of newly diagnosed multiple myeloma (NDMM). We investigated the outcomes of NDMM patients who failed to respond to bortezomib-based induction in a real-life clinical setting. In a cohort of 295 consecutive NDMM patients in 3 medical centers, 74 (25\%) failed to achieve at least partial response after 4 induction cycles, and were classified as non-responsive. Compared to induction responders, they were older, more frequently anemic, had a higher incidence of del17p and ISS-3, and a worse performance status. In multivariable analysis, bortezomib-based induction failure occurred in 25\% of patients and was the strongest independent factor predicting mortality with a 5-fold hazard ratio (95\% CI 1.44-8.68). Three-year overall survival in responsive vs. non-responsive patients were 76\% vs. 53\%, respectively (p < 0.0001). Survival from time of salvage second-line treatment was significantly shorter among induction non-responders vs. responders (25 months vs. not-reached, p = 0.024). {\textcopyright} 2015 Taylor \& Francis.},
	keywords = {bortezomib, induction, myeloma, resistance, Survival},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84953237562\&doi=10.3109\%2f10428194.2015.1121258\&partnerID=40\&md5=631ac299af6c7bfa4fa16b1dcfbfdab8},
	author = {Cohen, Y.C. and Joffe, E. and Benyamini, N. and Dimopoulos, M.A. and Terpos, E. and Trestman, S. and Held-Kuznetsov, V. and Avivi, I. and Kastritis, E.}
}
